Next, the tumor specificity for the widely recognized hematological malignancy CAR-T target,48,49 CD19, also significantly decreases when selectively downweighting the immune cell-producing blood cells and spleen (p = 8.54e−6; paired t test). The gene discussed is CD19; the disease is neoplasm.